Neal Ready
Duke University(US)Duke Medical Center(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Immunotherapy and Immune Responses
Most-Cited Works
- → Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer(2015)9,390 cited
- → Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer(2015)8,490 cited
- → First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer(2017)2,556 cited
- → Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study(2016)952 cited
- → Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)(2017)867 cited
- → Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer(2021)624 cited